Delivery Order SPE2DB22D3016-SPE2DB25FAUS6
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Enhertu 100 mg vials, a specialized oncology medication. This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $10,666.20 and is scheduled for completion by August 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Enhertu 100 mg vials, a specialty oncology pharmaceutical. This firm fixed-price delivery order, valued at $8,888.50 with an ultimate completion date of August 20, 2025, represents a non-competitive set-aside transaction under AmerisourceBergen's existing contract vehicle. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Enhertu 100 mg vials, valued at $17,777.00, with a completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $14,221.60 on June 30, 2025, for the supply of Enhertu 100 mg vials with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a pediatric-focused pharmaceutical procurement supporting federal medical supply requirements. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Enhertu 100 mg vials, a specialized oncology medication. This firm fixed-price delivery order, valued at $5,333.10, represents a non-set-aside competitive award with performance scheduled through June 24, 2025. The award will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of ENHERTU 100 mg vials, a specialty oncology pharmaceutical product. This competitive, non-set-aside delivery order carries a ceiling value of $14,221.60 with firm fixed pricing and is scheduled for completion by August 4, 2025. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,443.90 for 100 mg vials of Enhertu, a oncology therapeutic agent, with performance in Conshohocken, Pennsylvania and completion scheduled for May 13, 2025. This competitively awarded, firm fixed-price delivery order contains no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply framework with the federal government. This delivery order executes...
- The Defense Logistics Agency awarded a delivery order valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of October 7, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on September 16, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Enhertu 100 mg vials, valued at $8,888.50 with a firm fixed price arrangement. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation,...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FAUS6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Enhertu 100 mg vials, a specialty oncology medication. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $12,443.90 and is scheduled for completion by May 15, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. AmerisourceBergen's federal contract portfolio demonstrates consistent capability in delivering specialty pharmaceuticals, vaccines, and medical commodities across multiple therapeutic domains to military and veteran healthcare systems, positioning the company as a critical vendor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.4k | 4/24/25 |